Category:Antineoplastic agents

Subcategories

This category has the following 57 subcategories, out of 57 total.

Media in category "Antineoplastic agents"

The following 195 files are in this category, out of 195 total.

• 
  (±)-Mitotane Enantiomers Structural Formulae.png 2,099 × 620; 16 KB
  
• 
  1yy9.png 633 × 259; 68 KB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s005.ogv 33 s, 800 × 400; 9.71 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s006.ogv 33 s, 800 × 400; 8.65 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s007.ogv 33 s, 800 × 400; 8.83 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s008.ogv 33 s, 800 × 400; 8.07 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s009.ogv 33 s, 800 × 400; 7.89 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s010.ogv 33 s, 800 × 400; 8.74 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s011.ogv 33 s, 800 × 400; 7.34 MB
  
• A-chalcone-related-small-molecule-that-induces-methuosis-a-novel-form-of-non-apoptotic-cell-death-1476-4598-10-69-S1.ogv 1 min 0 s, 320 × 240; 1 MB
  
• A-chalcone-related-small-molecule-that-induces-methuosis-a-novel-form-of-non-apoptotic-cell-death-1476-4598-10-69-S2.ogv 1 min 0 s, 320 × 240; 580 KB
  
• A-Comprehensive-Panel-of-Three-Dimensional-Models-for-Studies-of-Prostate-Cancer-Growth-Invasion-pone.0010431.s013.ogv 1 min 6 s, 524 × 384; 8.71 MB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s1.ogv 12 s, 512 × 480; 348 KB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s2.ogv 12 s, 640 × 480; 337 KB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s3.ogv 12 s, 640 × 480; 600 KB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s4.ogv 40 s, 640 × 480; 3.45 MB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s5.ogv 13 s, 640 × 480; 631 KB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s2.ogv 25 s, 1,920 × 1,080; 8.73 MB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s3.ogv 6.3 s, 1,920 × 1,080; 342 KB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s4.ogv 6.3 s, 1,920 × 1,080; 1.05 MB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s5.ogv 3.2 s, 1,920 × 1,080; 1.53 MB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s6.ogv 3.2 s, 1,920 × 1,080; 2.12 MB
  
• A-phenanthrene-derived-PARP-inhibitor-is-an-extra-centrosomes-de-clustering-agent-exclusively-1471-2407-11-412-S1.ogv 16 s, 428 × 428; 975 KB
  
• A-phenanthrene-derived-PARP-inhibitor-is-an-extra-centrosomes-de-clustering-agent-exclusively-1471-2407-11-412-S2.ogv 2 min 10 s, 512 × 512; 1.38 MB
  
• A-spheroid-toxicity-assay-using-magnetic-3D-bioprinting-and-real-time-mobile-device-based-imaging-srep13987-s2.ogv 21 s, 640 × 360; 781 KB
  
• 
  Aceglatone.svg 512 × 471; 25 KB
  
• Advances-in-establishment-and-analysis-of-three-dimensional-tumor-spheroid-based-functional-assays-1741-7007-10-29-S4.ogv 29 s, 853 × 480; 3.22 MB
  
• Advances-in-establishment-and-analysis-of-three-dimensional-tumor-spheroid-based-functional-assays-1741-7007-10-29-S5.ogv 13 s, 853 × 480; 795 KB
  
• Advances-in-establishment-and-analysis-of-three-dimensional-tumor-spheroid-based-functional-assays-1741-7007-10-29-S6.ogv 12 s, 853 × 480; 270 KB
  
• 
  Anthramycin.svg 765 × 390; 17 KB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s2.ogv 42 s, 320 × 240; 2.8 MB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s3.ogv 59 s, 320 × 240; 2.97 MB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s4.ogv 42 s, 320 × 240; 2.22 MB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s5.ogv 45 s, 320 × 240; 805 KB
  
• Artificial-human-Met-agonists-based-on-macrocycle-scaffolds-ncomms7373-s2.ogv 15 s, 960 × 540; 2.45 MB
  
• 
  Aumolertinib.svg 945 × 565; 25 KB
  
• Autophagy-Facilitates-the-Development-of-Breast-Cancer-Resistance-to-the-Anti-HER2-Monoclonal-pone.0006251.s001.ogv 4.5 s, 1,024 × 576; 225 KB
  
• Autophagy-Facilitates-the-Development-of-Breast-Cancer-Resistance-to-the-Anti-HER2-Monoclonal-pone.0006251.s002.ogv 4.4 s, 856 × 480; 971 KB
  
• Autophagy-Facilitates-the-Development-of-Breast-Cancer-Resistance-to-the-Anti-HER2-Monoclonal-pone.0006251.s003.ogv 4.5 s, 856 × 480; 1.19 MB
  
• 
  Avutometinib ball-and-stick 7MFD.png 2,909 × 1,500; 639 KB
  
• 
  Avutometinib.svg 205 × 56; 15 KB
  
• 
  Belvarafenib.svg 264 × 70; 19 KB
  
• 
  Benzylguanine.svg 512 × 726; 15 KB
  
• 
  BI 811283 ball-and-stick 5K3Y.png 1,979 × 1,200; 532 KB
  
• 
  BI 811283.svg 184 × 124; 11 KB
  
• 
  Biosynthesis of nonproteinogenic amino acid.png 432 × 693; 12 KB
  
• 
  Brigimadlin.svg 810 × 550; 39 KB
  
• 
  Bropirimine structure.png 730 × 596; 7 KB
  
• 
  Bropirimine synthesis.png 1,647 × 266; 10 KB
  
• 
  Cedazuridine.svg 615 × 285; 13 KB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S3.ogv 21 s, 210 × 214; 1.17 MB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S4.ogv 28 s, 210 × 214; 663 KB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S5.ogv 28 s, 210 × 214; 676 KB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S6.ogv 28 s, 210 × 214; 855 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x6.ogv 13 s, 204 × 204; 216 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x7.ogv 8.5 s, 204 × 204; 224 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x8.ogv 13 s, 204 × 204; 304 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x9.ogv 19 s, 204 × 204; 369 KB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s002.ogv 29 s, 672 × 512; 2.94 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s003.ogv 33 s, 768 × 766; 2.3 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s004.ogv 50 s, 768 × 576; 6.85 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s005.ogv 32 s, 768 × 576; 5.18 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s006.ogv 21 s, 1,114 × 460; 13.17 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s007.ogv 21 s, 487 × 618; 720 KB
  
• 
  Daniquidone.svg 634 × 317; 3 KB
  
• Darinaparsin-Is-a-Multivalent-Chemotherapeutic-Which-Induces-Incomplete-Stress-Response-with-pone.0027699.s001.ogv 26 s, 518 × 514; 449 KB
  
• 
  Darinaparsin.svg 855 × 390; 17 KB
  
• 
  Dicycloplatin02.png 1,642 × 929; 88 KB
  
• 
  Enloplatin.png 692 × 269; 71 KB
  
• 
  Enloplatin.svg 115 × 62; 6 KB
  
• 
  Enzyme data for 4-substituted analogs.jpg 938 × 504; 49 KB
  
• 
  Enzyme data for monosubstituted 5-aryl analogs.jpg 1,173 × 866; 98 KB
  
• 
  Epacadostat.svg 512 × 212; 11 KB
  
• 
  Erbuzole structure.png 1,347 × 720; 16 KB
  
• 
  Exisulind structure.svg 512 × 292; 5 KB
  
• Exogenous-Ether-Lipids-Predominantly-Target-Mitochondria-pone.0031342.s006.ogv 28 s, 480 × 360; 8.69 MB
  
• 
  Glasdegib.svg 512 × 188; 5 KB
  
• 
  Golcadomide.svg 512 × 195; 9 KB
  
• High-Throughput-Ratio-Imaging-to-Profile-Caspase-Activity-Potential-Application-in-Multiparameter-pone.0020114.s001.ogv 3.8 s, 502 × 501; 1.2 MB
  
• High-Throughput-Ratio-Imaging-to-Profile-Caspase-Activity-Potential-Application-in-Multiparameter-pone.0020114.s002.ogv 3.9 s, 502 × 501; 3.7 MB
  
• 
  Hitachimycin.svg 512 × 295; 8 KB
  
• 
  Iberdomide.svg 512 × 180; 8 KB
  
• 
  Ibritumomab tiuxetan structure.svg 434 × 201; 61 KB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s1.ogv 9.0 s, 671 × 512; 2.61 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s2.ogv 9.0 s, 671 × 512; 2.91 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s3.ogv 9.0 s, 671 × 512; 3.52 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s4.ogv 9.0 s, 671 × 512; 3.27 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s5.ogv 9.0 s, 671 × 512; 4.61 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s6.ogv 9.0 s, 671 × 512; 2.34 MB
  
• In-silico-Experimentation-of-Glioma-Microenvironment-Development-and-Anti-tumor-Therapy-pcbi.1002355.s015.ogv 0.0 s, 432 × 336; 16.02 MB
  
• In-silico-Experimentation-of-Glioma-Microenvironment-Development-and-Anti-tumor-Therapy-pcbi.1002355.s016.ogv 0.0 s, 432 × 336; 11.97 MB
  
• In-silico-Experimentation-of-Glioma-Microenvironment-Development-and-Anti-tumor-Therapy-pcbi.1002355.s017.ogv 0.0 s, 432 × 336; 15.38 MB
  
• In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s5.ogv 12 s, 1,920 × 1,080; 3.29 MB
  
• In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s6.ogv 12 s, 1,920 × 1,080; 6.59 MB
  
• In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s7.ogv 12 s, 1,920 × 1,080; 3.44 MB
  
• In-vivo-Bioimaging-as-a-Novel-Strategy-to-Detect-Doxorubicin-Induced-Damage-to-Gonadal-Blood-Vessels-pone.0023492.s003.ogv 1 min 29 s, 480 × 336; 2.73 MB
  
• In-vivo-Bioimaging-as-a-Novel-Strategy-to-Detect-Doxorubicin-Induced-Damage-to-Gonadal-Blood-Vessels-pone.0023492.s004.ogv 5 min 14 s, 480 × 336; 11.62 MB
  
• 
  Irofulven.png 4,299 × 650; 48 KB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s008.ogv 20 s, 512 × 464; 1.41 MB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s009.ogv 30 s, 512 × 465; 4.62 MB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s010.ogv 13 s, 512 × 464; 357 KB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s011.ogv 20 s, 640 × 480; 217 KB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s012.ogv 20 s, 1,281 × 961; 989 KB
  
• 
  Ivosidenib.svg 512 × 385; 8 KB
  
• 
  Leptomycin B.svg 2,558 × 986; 4 KB
  
• 
  Linifanib skeletal.svg 314 × 133; 30 KB
  
• 
  Lobaplatin.svg 268 × 101; 48 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s1.ogv 14 s, 143 × 143; 279 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s10.ogv 13 s, 110 × 110; 131 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s11.ogv 46 s, 72 × 72; 86 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s12.ogv 37 s, 72 × 72; 152 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s13.ogv 36 s, 72 × 72; 109 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s14.ogv 41 s, 160 × 160; 1.15 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s15.ogv 21 s, 120 × 120; 435 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s16.ogv 35 s, 200 × 200; 900 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s17.ogv 50 s, 140 × 140; 1.04 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s18.ogv 53 s, 130 × 130; 1.18 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s2.ogv 48 s, 230 × 230; 954 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s3.ogv 31 s, 133 × 133; 734 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s4.ogv 1 min 12 s, 120 × 120; 1.33 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s5.ogv 58 s, 150 × 150; 856 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s6.ogv 16 s, 130 × 130; 318 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s7.ogv 33 s, 90 × 90; 50 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s8.ogv 29 s, 127 × 127; 390 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s9.ogv 12 s, 200 × 200; 620 KB
  
• 
  Lurbinectedin structure.svg 512 × 357; 13 KB
  
• 
  Lurbinectedin.png 1,647 × 1,453; 141 KB
  
• 
  Mecanisme d'acció Pyr1.jpg 462 × 577; 52 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s006.ogv 7.3 s, 264 × 203; 322 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s007.ogv 9.2 s, 264 × 203; 280 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s008.ogv 11 s, 198 × 152; 210 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s009.ogv 11 s, 198 × 152; 277 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s010.ogv 15 s, 174 × 133; 205 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s011.ogv 15 s, 174 × 133; 87 KB
  
• Methyl-Sulfone-Induces-Loss-of-Metastatic-Properties-and-Reemergence-of-Normal-Phenotypes-in-a-pone.0011788.s001.ogv 6.0 s, 312 × 240; 727 KB
  
• Methyl-Sulfone-Induces-Loss-of-Metastatic-Properties-and-Reemergence-of-Normal-Phenotypes-in-a-pone.0011788.s002.ogv 1.9 s, 312 × 240; 358 KB
  
• Methylsulfonylmethane-Suppresses-Breast-Cancer-Growth-by-Down-Regulating-STAT3-and-STAT5b-Pathways-pone.0033361.s001.ogv 29 s, 480 × 320; 2.47 MB
  
• Methylsulfonylmethane-Suppresses-Breast-Cancer-Growth-by-Down-Regulating-STAT3-and-STAT5b-Pathways-pone.0033361.s002.ogv 29 s, 480 × 320; 1.39 MB
  
• 
  Mezigdomide.svg 512 × 200; 9 KB
  
• 
  Monomethylauristatin E.svg 512 × 249; 73 KB
  
• 
  Monomethylauristatin F.svg 1,105 × 600; 33 KB
  
• 
  Nandrolone 17-bis(2-chloroethyl)carbamate.svg 1,670 × 990; 29 KB
  
• 
  Navitoclax.svg 2,625 × 1,500; 40 KB
  
• 
  Nedaplatin 3D BS.png 2,385 × 1,878; 477 KB
  
• Oblongifolin-C-inhibits-metastasis-by-up-regulating-keratin-18-and-tubulins-srep10293-s2.ogv 14 s, 1,365 × 1,024; 52.06 MB
  
• Oblongifolin-C-inhibits-metastasis-by-up-regulating-keratin-18-and-tubulins-srep10293-s3.ogv 14 s, 1,365 × 1,024; 51.8 MB
  
• 
  Olutasidenib.svg 790 × 385; 19 KB
  
• Oxytocin-evokes-a-pulsatile-PGE2-release-from-ileum-mucosa-and-is-required-for-repair-of-intestinal-srep11731-s2.ogv 44 s, 720 × 720; 14.67 MB
  
• 
  P-Tosylaminocaprylchlormethylketon Synthese.svg 410 × 199; 52 KB
  
• 
  Padeliporfin.png 1,767 × 1,944; 161 KB
  
• 
  Pegdinetanib non-peptide structure.svg 541 × 183; 39 KB
  
• 
  Picoplatin.png 1,126 × 872; 15 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S1.ogv 0.6 s, 636 × 432; 216 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S2.ogv 0.6 s, 636 × 432; 151 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S3.ogv 0.6 s, 636 × 432; 192 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S4.ogv 0.6 s, 636 × 432; 197 KB
  
• 
  Plicamycin.svg 2,576 × 1,705; 27 KB
  
• 
  Porfimer Sodium.png 4,195 × 1,593; 85 KB
  
• 
  Quisinostat.svg 512 × 242; 6 KB
  
• 
  Salinosporamide A Biosynthesis.png 1,568 × 1,330; 34 KB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S1.ogv 28 s, 400 × 250; 390 KB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S2.ogv 28 s, 400 × 250; 1.36 MB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S3.ogv 28 s, 400 × 250; 639 KB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S4.ogv 28 s, 343 × 253; 685 KB
  
• 
  Selinexor.svg 512 × 281; 7 KB
  
• Semaphorin-3A-Suppresses-Tumor-Growth-and-Metastasis-in-Mice-Melanoma-Model-pone.0033633.s005.ogv 11 s, 176 × 144; 515 KB
  
• Semaphorin-3A-Suppresses-Tumor-Growth-and-Metastasis-in-Mice-Melanoma-Model-pone.0033633.s006.ogv 11 s, 176 × 144; 426 KB
  
• Semaphorin-3A-Suppresses-Tumor-Growth-and-Metastasis-in-Mice-Melanoma-Model-pone.0033633.s007.ogv 11 s, 176 × 144; 413 KB
  
• 
  Streptovitacin A.svg 1,170 × 940; 19 KB
  
• Structure-and-Function-of-ABCG2-Rich-Extracellular-Vesicles-Mediating-Multidrug-Resistance-pone.0016007.s005.ogv 2.4 s, 1,024 × 1,024; 277 KB
  
• Structure-and-Function-of-ABCG2-Rich-Extracellular-Vesicles-Mediating-Multidrug-Resistance-pone.0016007.s006.ogv 3.0 s, 512 × 520; 256 KB
  
• 
  STX-140.svg 167 × 118; 22 KB
  
• 
  Tabla antineoplasicos.png 973 × 327; 18 KB
  
• 
  Talampanel skeletal.svg 512 × 507; 5 KB
  
• 
  Talirine skeletal.svg 1,207 × 561; 18 KB
  
• 
  Targaprimir 96.svg 1,568 × 832; 44 KB
  
• 
  Targaprimir-96-CA-Biotin (1).svg 1,568 × 1,249; 57 KB
  
• 
  Targaprimir-96-CA-Biotin (2).svg 1,574 × 1,049; 56 KB
  
• 
  Targaprimir-96-CA-Biotin (3).svg 1,574 × 1,049; 59 KB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s2.ogv 13 s, 1,280 × 960; 624 KB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s3.ogv 19 s, 1,280 × 960; 615 KB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s4.ogv 19 s, 1,280 × 960; 1.31 MB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s5.ogv 19 s, 1,280 × 960; 1.36 MB
  
• 
  Tesirine skeletal.svg 1,216 × 660; 21 KB
  
• Thymosin-β10-Expression-Driven-by-the-Human-TERT-Promoter-Induces-Ovarian-Cancer-Specific-Apoptosis-pone.0035399.s001.ogv 26 s, 480 × 480; 4.58 MB
  
• 
  Trabectedin Biosynthesis.png 11,033 × 7,093; 2.96 MB
  
• 
  Trabectedin labeled-rings.gif 1,053 × 758; 14 KB
  
• 
  Trabectedin structure.svg 512 × 385; 13 KB
  
• 
  Trabectedin.svg 491 × 395; 34 KB
  
• 
  U-11,555 image.png 1,211 × 843; 16 KB
  
• 
  Uvaricin.svg 2,261 × 1,569; 3 KB
  
• 
  Vadimezan.png 561 × 438; 7 KB
  
• 
  Vapreotide.svg 512 × 461; 72 KB
  
• 
  Vintafolide.svg 512 × 497; 131 KB
  
• 
  Y-90 tacatuzumab tetraxetan structure.svg 292 × 174; 64 KB